@article{ref1,
title="[Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders]",
journal="Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova",
year="2018",
author="Yakovleva, Yu A. and Yanaeva, A. N. and Spikina, A. A. and Rukavitsyna, E. L.",
volume="118",
number="10. Vyp. 2",
pages="98-104",
abstract="In this article, the results of personal prospective observation of lacosamide (LCM) administration in 91 adults with epilepsy and comorbid mental disorders are presented. LCM was administered as a part of polytherapy for 80 patients at a dose of up to 400 mg/day and of monotherapy for 11 patients at a dose of up to 600 mg/day for up to 12 months. Clinical-psychopathological and experimental-psychological monitoring of patients' condition over time was carried out using the Mental Health Comprehensive Assessment Scale (MHCAS), the Global Clinical Impression scale (GCI). As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration.<p /><p>Language: ru</p>",
language="ru",
issn="1997-7298",
doi="10.17116/jnevro201811810298",
url="http://dx.doi.org/10.17116/jnevro201811810298"
}